X

Cystic Fibrosis Therapy Diminishes Hyper-Inflammation In COVID-19-Related Pneumonia

Michelle Flores, Pharm D Candidate c/o 2027 According to clinical trial results from researchers at UCL, UCLH, and the Francis…

eMAR

An Investigation into the White House Pharmacy

By Holly Nguyen, PharmD Candidate c/o 2024 The White House Medical Unit employs a small confidential team of healthcare professionals,…

eMAR

Utilization of Tumor Microenvironment in the treatment of Breast Cancer

By: Sameen Siddiqui, PharmD Candidate c/o 2025, Madelyn Lombardo, PharmD Candidate c/o 2027, and Gabriella Lamantea, PharmD Candidate c/o 2027…

eMAR

Intratumoral and Gut Microbiota Roles in Cancer Treatment

By: Ariella Zadrima, PharmD Candidate c/o 2026 Introduction Cancer is a disease state in which abnormal cells in the body…

eMAR

E.mbrace the novel E. coli Vaccine

By Ashley Dao, PharmD Candidate c/o 2024 Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacilli and is…

eMAR

Deciphering D&Ds: A Peer-Led Piece Containing an Academic Overview, Study Tips, and Analysis

By: Ashley Medina, PharmD Candidate c/o 2025 Embarking on the professional years of St. John’s Pharmacy curriculum allows the aspiring…

eMAR

Carbapenem Resistant Acinetobacter Baumannii: An Urgent Threat

By: Giavanna Carr, PharmD Candidate c/o 2025 Acinetobacter is a gram-negative organism typically found in soil and water, but it…

eMAR

Revolutionizing ADPKD Treatment: Breakthrough Drug Unveils Unprecedented Benefits

By: Bhojranie Brahmanand, PharmD Candidate c/o 2025 The most prevalent manifestation within the spectrum of polycystic kidney diseases is recognized…

eMAR

FDA Approves Litfulo for Adults and Adolescents with Severe Alopecia Areata

By: Anjali Thykattil, PharmD Candidate c/o 2025 and Isabelle Lim, PharmD Candidate c/o 2024 Effective June 23rd, 2023, the United…

eMAR

Utilization of Tumor Microenvironment in the Treatment of Breast Cancer

By: Sameen Siddiqui, PharmD Candidate c/o 2025, Madelyn Lombardo, PharmD Candidate c/o 2027, and Gabriella Lamantea, PharmD Candidate c/o 2027…

eMAR